Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13952183 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL791505 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL265072 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL10556768 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL301766 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL3382944 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL9885352 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL11930055 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL6917395 | 0.97 | EPHX1 (0.60) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL12529955 | 0.97 | EPHX1 (0.60) | EPHX1CA1CA2CA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720065-B1 | Photosensitive lithographic printing plate | FUJIFILM CORP (JP) | 2017-06-14 | — | — | EP | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-7473694-B2 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2009-01-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| EP-0884309-B1 | Optically active compound, antiferroelectric liquid crystal composition containing the same, process for producing the same and process for producing optically active carboxylic acid | SEMICONDUCTOR ENERGY LAB (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-5965059-A | Optically active compound, antiferroelectric liquid crystal composition containing the same, process for producing the same and process for producing an optically active carboxylic acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0884309-A1 | Optically active compound, antiferroelectric liquid crystal composition containing the same, process for producing the same and process for producing optically active carboxylic acid | Takasago International Corporation (JP) | 1998-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | EPHX1 1767/4885CA1 4618/4885CA2 1044/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885CA1 4507/4885CA2 3976/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | EPHX1 3501/4885CA1 2793/4885CA2 840/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | EPHX1 591/4885CA1 1075/4885CA2 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.